stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / SUPN / Revenue

Supernus Pharmaceuticals, Inc. Revenue 2010–2025

Supernus Pharmaceuticals, Inc. (SUPN) annual revenue by fiscal year, computed from SEC filings. Compound growth +80.1%/yr over 15 years.

Fiscal yearRevenueChange (YoY)
FY 2025$718.95M+8.6%
FY 2024$661.82M+8.9%
FY 2023$607.52M-8.9%
FY 2022$667.24M+15.1%
FY 2021$579.77M+11.4%
FY 2020$520.40M+32.5%
FY 2019$392.75M-3.9%
FY 2018$408.90M+35.3%
FY 2017$302.24M+40.6%
FY 2016$215.00M+45.8%
FY 2015$147.47M+59.1%
FY 2014$92.68M+671.1%
FY 2013$12.02M+712.1%
FY 2012$1.48M+84.3%
FY 2011$803,000+657.5%
FY 2010$106,000

Source: Supernus Pharmaceuticals, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Supernus Pharmaceuticals, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Supernus Pharmaceuticals, Inc. — frequently asked questions

What is Supernus Pharmaceuticals, Inc.'s revenue?

Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $718.95M for fiscal year 2025, per its SEC filings.

How has Supernus Pharmaceuticals, Inc.'s revenue changed over time?

Between fiscal 2010 and 2025, SUPN's revenue grew at roughly 80.1% per year (compound annual rate), from $106,000 to $718.95M.

Where does this data come from?

Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More SUPN financial history

Full SUPN fundamentals page → · All 1,500+ companies →